Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.98 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 6/20 | 0.40 |
| ▸ | CASP1 | P29466 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metralindole SCHEMBL29414121 | 1.00 | KDM4E (0.98) | KDM4EHSD17B10HPGDHIF1AMEN1 | |
| Metralindole SCHEMBL3130721 | 0.99 | KDM4E (1.00) | KDM4EHSD17B10HPGDHIF1AMEN1 | |
| Metralindole SCHEMBL1650251 | 0.98 | KDM4E (0.93) | KDM4EHSD17B10HPGDHIF1AMEN1 | |
| Metralindole SCHEMBL28860324 | 0.78 | KDM4E (0.59) | KDM4EHSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL11205818 | 0.74 | KDM4E (0.70) | KDM4EHSD17B10HPGDHIF1AMEN1 | |
| Hydrochloric Acid SCHEMBL11234309 | 0.73 | KDM4E (0.72) | KDM4EHSD17B10HPGDHIF1AMEN1 | |
| SCHEMBL29521380 | 0.68 | HTR6 (0.51) | KDM4EHSD17B10HIF1AMEN1KMT2A | |
| SCHEMBL4056262 | 0.67 | KDM4E (0.49) | KDM4EHSD17B10HPGDHIF1AMEN1 | |
| SCHEMBL4699104 | 0.65 | KDM4E (0.47) | KDM4EHSD17B10HPGDMEN1KMT2A | |
| SCHEMBL13219185 | 0.64 | HSD17B10 (0.46) | KDM4EHSD17B10HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2080 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2024130044-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | LUMINOUS MIND INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024098098-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural MedTech Pty Ltd (AU) | 2024-05-16 | — | — | WO | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | claimed |
| US-20060258715-A1 | Therapeutic combinations for the treatment or prevention of depression | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| WO-2006116149-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2005102366-A2 | LITHIUM COMBINATIONS, AND USES RELATED THERETO | SATOW PHILIP MAXWELL (US) | 2005-11-03 | — | — | WO | claimed |
| US-20050233010-A1 | Lithium combinations, and uses related thereto | NOVEN THERAPEUTICS, LLC | 2005-10-20 | — | — | US | claimed |
| WO-2005084654-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS | PHARMACIA CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| US-20020019421-A1 | Compositions and therapy for substance addiction | BIBERMAN RONI (IL) | 2002-02-14 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |